GREY:DGCRF - Post by User
Post by
ready2go1on Jul 31, 2009 12:22pm
221 Views
Post# 16182150
The Call
The CallGen-Probe reported last night and as you can see by their share price, investors were not happy with their performance of the blood testing business. That was the focus of the call and questions, although they did mention several times the value of their pipeline/PCA3. There was however one question about PCA3. Gen-Probe said that they were pleased with how PCA3 sales are ramping up and that with additional sales reps in Europe being added they should continue to see them grow; 70% year over year growth. The U.S. FDA trial will begin in a few weeks and should take less than a year. I expect gpro to focus on pca3 because they know the value of the test and the revenue that it will bring the company. All we need to see now is someone take out the current seller that has really dragged us down over the past year. I expect that once that is done we could finish the year at $2.00 and move up from there.